[go: up one dir, main page]

DE602007006010D1 - Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten - Google Patents

Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Info

Publication number
DE602007006010D1
DE602007006010D1 DE602007006010T DE602007006010T DE602007006010D1 DE 602007006010 D1 DE602007006010 D1 DE 602007006010D1 DE 602007006010 T DE602007006010 T DE 602007006010T DE 602007006010 T DE602007006010 T DE 602007006010T DE 602007006010 D1 DE602007006010 D1 DE 602007006010D1
Authority
DE
Germany
Prior art keywords
compounds
treatment
triazolopyrazin
degenerative
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006010T
Other languages
English (en)
Inventor
Martin James Inglis Andrews
Paul Edwards
Mark Stuart Chambers
Wolfgang Schmidt
Juha Andrew Clase
Gregory Bar
Kim Louise Hirst
Angus Macleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of DE602007006010D1 publication Critical patent/DE602007006010D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602007006010T 2006-05-31 2007-05-30 Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten Active DE602007006010D1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80355206P 2006-05-31 2006-05-31
US93176407P 2007-05-25 2007-05-25
US93176307P 2007-05-25 2007-05-25
US93184407P 2007-05-25 2007-05-25
US93210007P 2007-05-29 2007-05-29
PCT/EP2007/055246 WO2007138072A2 (en) 2006-05-31 2007-05-30 Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases

Publications (1)

Publication Number Publication Date
DE602007006010D1 true DE602007006010D1 (de) 2010-06-02

Family

ID=38618932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006010T Active DE602007006010D1 (de) 2006-05-31 2007-05-30 Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten

Country Status (20)

Country Link
US (3) US7501411B2 (de)
JP (1) JP2009538877A (de)
KR (1) KR20090026288A (de)
AT (1) ATE465164T1 (de)
AU (1) AU2007267121A1 (de)
BR (1) BRPI0712531A2 (de)
CA (1) CA2653506A1 (de)
CR (1) CR10458A (de)
DE (1) DE602007006010D1 (de)
DK (1) DK2029602T3 (de)
EA (1) EA200870592A1 (de)
EC (1) ECSP088923A (de)
HR (1) HRP20100378T1 (de)
IL (1) IL195033A0 (de)
MX (1) MX2008015057A (de)
NI (1) NI200800299A (de)
NO (1) NO20084703L (de)
NZ (1) NZ573015A (de)
PT (1) PT2029602E (de)
WO (1) WO2007138072A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308879A1 (de) 2004-04-02 2011-04-13 OSI Pharmaceuticals, Inc. 6,6-bizyklische ringsubstituierte heterobizyklische Proteinkinasehemmer
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
KR20090026288A (ko) * 2006-05-31 2009-03-12 갈라파고스 엔.브이. 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
US8133895B2 (en) * 2007-05-10 2012-03-13 Janssen Pharmaceutica N.V. Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
CL2009001064A1 (es) * 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2343297A1 (de) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
EP2825540B1 (de) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituierte imidazopyridazine
EP3008062B1 (de) 2013-06-11 2017-04-05 Bayer Pharma Aktiengesellschaft Prodrugderivate aus substituierten triazolopyridinen
JP6435323B2 (ja) * 2013-06-19 2018-12-05 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規化合物及びその医薬組成物
WO2015101622A1 (de) 2014-01-03 2015-07-09 Bayer Cropscience Ag Neue pyrazolyl-heteroarylamide als schädlingsbekämpfungsmittel
EP3137454A1 (de) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
RU2018101897A (ru) 2015-06-22 2019-07-24 Сумитомо Дайниппон Фарма Ко., Лтд. Бициклическое гетероциклическое амидное производное
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
TWI806832B (zh) 2016-07-12 2023-07-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
CN109206357A (zh) * 2017-07-04 2019-01-15 浙江九洲药业股份有限公司 一种格列齐特中间体的通式化合物及其制备方法和应用
AU2018313094A1 (en) 2017-08-07 2020-02-20 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
WO2019118909A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
MX2020008949A (es) 2018-02-27 2021-01-08 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
CN108379583B (zh) * 2018-03-27 2021-08-17 北京大学 一种肿瘤转移药物治疗的靶标及其应用
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
IL279829B2 (en) 2018-07-05 2025-05-01 Incyte Holdings Corp Fused pyrazine derivatives as A2A/A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2021168734A1 (zh) * 2020-02-27 2021-09-02 世延生医股份有限公司 基质金属蛋白酶1的单克隆抗体、其检测试剂盒及其检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194152A4 (de) 1999-06-30 2002-11-06 Merck & Co Inc Verbindungen zur SRC Kinase-Hemmung
AU779197B2 (en) 1999-10-08 2005-01-13 Grunenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives
CZ20021242A3 (cs) 1999-10-08 2002-08-14 Grünenthal GmbH Bicyklické deriváty imidazo-5-yl-aminu, způsob jejich výroby, jejich pouľití a léčiva tyto látky obsahující
MXPA02003547A (es) 1999-10-08 2002-09-18 Gr Nenthal Gmbh Derivados biciclos de imidazo-3-il-amina substituidos en el sexto anillo.
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
NO20003636A (no) 2000-07-14 2001-11-26 Zopa As Fremgangsmåte og anordning for kjøling av produkter i et transportsystem
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
EP1363702A4 (de) * 2001-01-30 2007-08-22 Cytopia Pty Ltd Verfahren zur hemmung von kinasen
CA2482991A1 (en) * 2002-04-19 2003-10-30 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
US6919341B2 (en) * 2002-09-23 2005-07-19 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1615931A1 (de) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazine und verfahren zu deren herstellung und anwendung
ATE525377T1 (de) * 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
DE602005013085D1 (de) 2004-06-09 2009-04-16 Oncalis Ag Proteinkinaseinhibitoren
CN101098870B (zh) 2004-11-08 2010-11-03 万有制药株式会社 新型稠环咪唑衍生物
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US20060149535A1 (en) * 2004-12-30 2006-07-06 Lg Electronics Inc. Method for controlling speed of audio signals
WO2006086545A2 (en) 2005-02-08 2006-08-17 Robert W Desimone Method to identify novel therapeutics
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
EP1945644A2 (de) 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazine als proteinkinase-hemmer
US20070105864A1 (en) 2005-11-10 2007-05-10 Schering Corporation Methods for inhibiting protein kinases
US7732609B2 (en) 2005-12-01 2010-06-08 Elan Pharmaceuticals, Inc. 5-(arylsulfonyl)-pyrazolopiperidines
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
KR20090026288A (ko) * 2006-05-31 2009-03-12 갈라파고스 엔.브이. 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors

Also Published As

Publication number Publication date
US20110178067A1 (en) 2011-07-21
US7915256B2 (en) 2011-03-29
IL195033A0 (en) 2009-08-03
ATE465164T1 (de) 2010-05-15
DK2029602T3 (da) 2010-08-09
HRP20100378T1 (hr) 2010-08-31
WO2007138072A3 (en) 2008-02-14
JP2009538877A (ja) 2009-11-12
CR10458A (es) 2009-02-26
NO20084703L (no) 2009-02-19
US20080090818A1 (en) 2008-04-17
MX2008015057A (es) 2008-12-10
NI200800299A (es) 2010-05-25
ECSP088923A (es) 2009-01-30
NZ573015A (en) 2010-11-26
AU2007267121A1 (en) 2007-12-06
US20100298300A1 (en) 2010-11-25
US7501411B2 (en) 2009-03-10
EA200870592A1 (ru) 2009-08-28
KR20090026288A (ko) 2009-03-12
BRPI0712531A2 (pt) 2012-12-25
CA2653506A1 (en) 2007-12-06
WO2007138072A2 (en) 2007-12-06
PT2029602E (pt) 2010-07-08

Similar Documents

Publication Publication Date Title
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2005034870A3 (en) Amide compounds and ion channel ligands and uses thereof
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
EP2215054B8 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
EA201071275A1 (ru) Конденсированные соединения пиразина, которые можно использовать для лечения дегенеративных и воспалительных заболеваний
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
ATE500236T1 (de) Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2005105770A3 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
WO2006099410A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
TNSN07283A1 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005105766A3 (en) Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them
GB2452142A (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2012078674A8 (en) Substituted indole/indazole-pyrimidinyl compounds
WO2006138589A3 (en) Opioid receptor ligands

Legal Events

Date Code Title Description
8364 No opposition during term of opposition